JPRN-jRCT2080220874未知2 期
Phase 2 open study Exploratory examination of efficacy and safety of paricalcitol injection and maxacalcitol injection in chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism
Abbott Japan Co., Ltd.0 个研究点目标入组 45 人开始时间: 2009年10月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •CKD patients with iPTH >=300pg/mL, adjusted Ca 8.4<= - <10.2 mg/dL, P <=6.5 mg/d
排除标准
- •Patients taking drugs that affect iPTH, calcium or bone metabolism
研究者
相似试验
进行中（未招募）
不适用
Estudio abierto de fase II para evaluar los posibles marcadores tumorales predictivos en pacientes con cáncer colorrectal metastásico y tumor con KRAS no mutado tratados con FOLFOX6m y panitumumab como tratamiento de primera línea.Pacientes con cáncer colorrectal metastásico y tumor con KRAS no mutado tratados con FOLFOX6m y Panitumumab como tratamiento de primera líneaEUCTR2009-017331-18-ESGrupo Español Multidisciplinar en Cáncer Digestivo-GEMCAD
进行中（未招募）
不适用
ncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Studymoderate to severe palmoplantar pustular psoriasisMedDRA version: 9.1Level: LLTClassification code 10037159Term: Psoriasis pustularEUCTR2007-003922-70-DETechnische Universität Dresden42
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapyMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2018-004788-30-FR4SC AG40
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.EUCTR2018-004788-30-NL4SC AG40
进行中（未招募）
1 期
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 studyEUCTR2018-004788-30-IT4SC AG40